期刊文献+

抗动脉粥样硬化核酸疫苗纳米冻干剂的研究 被引量:2

Study on Lyophilized Nanoparticles of Antiatherosclerotic DNA Vaccine
下载PDF
导出
摘要 目的:碱裂解法提取编码胆固醇酯转运蛋白的质粒(简称pCETP)作为核酸疫苗,并制成适合鼻腔递送的载核酸疫苗壳聚糖纳米冻干剂。方法:碱裂解法大量提取抗动脉粥样硬化核酸疫苗,以壳聚糖(简称CS)为非病毒载体,复凝聚法制备pCETP/CS纳米粒,正交设计筛选最佳pCETP/CS纳米冻干剂处方。结果:提取了纯度可靠的pCETP,制得的pCETP/CS冻干剂具有较高的包封率(94.6%)和载药量(27.3%),重分散后纳米粒粒径为(375±18)nm,pCETP浓度可达4000μg.mL-1,较冻干前提高40倍。结论:pCETP/CS冻干剂具有良好的稳定性和重分散性,为适合鼻内递送的载基因微粒制剂,具有较好的研究前景。 Objective: The plasmid encoding cholesterol ester transfer protein (pCETP) extracted by alkaline lysis approach, was used to prepare pCETP/Chitosan(CS) lyophilized nanopartieles for nasal mucosa administration. Methods: Alkaline lysis method was used for extracting pCETP as antiatheroselerosis DNA vaccine. The pCETP loaded chitosan nanoparticles were prepared by the complex eoacervation method. Results: The obtained purity of pCETP was reliable. By the orthogonal design, the optimized freeze-drying formulation led to high encapsulating efficiency(94.6%) and drug-loading content(27.3%). The size of the redispersed nanoparticles was (375±18)nm, and the concentration of pCETP was as high as 4000μg·ml^-1. Furthermore, the volume of the administration was reduced as much as 40 fold, compared with the volume before freeze-drying. Conclusion: The pCETP/CS freeze-dried complex with good stability and redispersibility is a potential immunization formulation for nasal mucosa administration and worthy for further exploitation.
出处 《药学与临床研究》 2011年第2期107-111,共5页 Pharmaceutical and Clinical Research
基金 国家自然科学基金(No.30572272)
关键词 动脉粥样硬化 核酸疫苗 壳聚糖 纳米粒 冻干剂 Atherosclerosis DNA vaccine Chitosan Nanoparticles Lyophilization
  • 相关文献

参考文献5

  • 1Kim TH,Jiang HL,Jere D,et al.Chemical modification of chitosan as a gene carrier in vitro and in vivo[J].Prog Polym Sci,2007,32(7):726-53.
  • 2Mao SR,Sun W,Kissel T.Chitosan-based formulations for delivery of DNA and siRNA[J].Adv Drug Deliv Rev,2010,62(1):12-27.
  • 3Barter PJ,Kastelein JJ.Targeting cholesterol ester transfer protein for the prevention and management of cardiovascular disease[J].J Am Coll Cardiol,2006,47(3):492-9.
  • 4Khatri K,Goyal AK,Gupta PN,et al.Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B[J].Int J Pharm,2008,354(1-2):235-41.
  • 5Costantino HR,Carrasquillo KG,Cordero RA,et aL Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone[J].J Pharm Sci,1998,87(11):1412-20.

同被引文献37

  • 1Liu J, Hu W, Chen H B, et al. Isotretinoin-loaded solid lipidwith skin targeting for topical delivery [ J ]. Int J Pharm, 2007,328(2) :191-195.
  • 2TERLEGA K, LATOCHA M. Nanotechnology fu- ture of medicine[J]. Pol Merkur Lekarski, 2012, 33: 229--232.
  • 3JABIR N R, TABREZ S, ASHRAF G M, et al. Nanotechnology-based approaches in anticancer re- search[J]. Int J Nanomedicine, 2012, 7: 4391- 4408.
  • 4YANG G, WANG Y, ZENG Y, et al. Rapid health transition in China, 1990- 2010= findings from the Global Burden of Disease Study 2010[J]. Lancet, 2013, 381=1987--2015.
  • 5KAMALY N, FREDMAN G, SUBRAMANIAN M, et al. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles[J]. Proc Natl Acad Sci U S A, 2013, 110= 6506--6511.
  • 6LOBATTO M E, FAYAD Z A, SILVERA S, et al. Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experi- mental atherosclerosis[J]. Mol Pharm, 2010, 7:2020 --2029.
  • 7ENIOLA-ADEFESO O, HESLINGA M J, PORTER T M. Design of nanovectors for therapy and imaging of cardiovascular diseases[J]. Methodist Debakey Cardiovasc J, 2012, 8: 13-17.
  • 8XIA P, VADAS M A, RYE K A, et al. High density lipoproteins (HDL) interrupt the sphingosine kinasesignaling pathway. A possible mechanism for protec- tion against atherosclerosis by HDL[J]. J Biol Chem, 1999, 274:33143--33147.
  • 9WADHAM C, ALBANESE N, ROBERTS J, et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity[J]. Circulation, 2004, 109: 2116--2122.
  • 10BESLER C, LUSCHER T F, LANDMESSER U. Molecular mechanisms of vascular effects of High- density lipoprotein: alterations in cardiovascular dis- ease[J]. EMBO Mol Med, 2012, 4: 251--268.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部